Endocrine Practice最新文献

Info for Readers/Subscription page 读者信息/订阅页面

IF 3.7 3区医学

Endocrine Practice Pub Date : 2025-07-24 DOI: 10.1016/S1530-891X(25)00949-8

引用次数: 0

Advances in Islet Function Replacing Strategies After Total Pancreatectomy. 全胰切除术后胰岛功能替代策略的研究进展。

IF 3.7 3区医学

Endocrine Practice Pub Date : 2025-07-22 DOI: 10.1016/j.eprac.2025.07.012

Siyuan Peng, Bo Zhao, Xiaolei Yi, Xuhui Li, Jun Zhang, Jie Wang, Ruineng Li

引用次数: 0

Implications of GLP-1 Receptor Agonists on Thyroid Function and Thyroid Nodules: A Drug Target Mendelian Randomization and Cohort Study. GLP-1受体激动剂对甲状腺功能和甲状腺结节的影响：一项药物靶向孟德尔随机和队列研究。

IF 3.7 3区医学

Endocrine Practice Pub Date : 2025-07-22 DOI: 10.1016/j.eprac.2025.07.013

Zhijun Zhang, Jingyun Yang, Ling Gao

{"title":"Implications of GLP-1 Receptor Agonists on Thyroid Function and Thyroid Nodules: A Drug Target Mendelian Randomization and Cohort Study.","authors":"Zhijun Zhang, Jingyun Yang, Ling Gao","doi":"10.1016/j.eprac.2025.07.013","DOIUrl":"https://doi.org/10.1016/j.eprac.2025.07.013","url":null,"abstract":"Objectives: GLP-1 receptor agonists are antidiabetic medications, with conflicting reports about their relationship with thyroid diseases. This study investigates their effects on thyroid function and nodules in patients with diabetes.Methods: Mendelian randomization (MR) was conducted to examine the association between genetically proxied GLP-1 receptor agonist activity and thyroid diseases. This was followed by a cohort study involving 169 patients with diabetes, who were divided into a control group (Control group, W/O GLP-1 treatment) and a GLP-1 receptor agonist treatment group (GLP-1RAs group) based on their medication usage. Patients' thyroid function tests, thyroid nodule diameters and TI-RADS classifications were compared at baseline and after 12 months of treatment.Results: Through MR, GLP-1 receptor agonists decrease fT4 levels within the normal range [OR (95% CI) = 0.9948 (0.9936-0.9961), P<0.001]. Cohort study showed that after treatment, the nodule diameter increased in both the Control group (0.69 vs. 0.77, p=0.004) and the GLP-1 group (0.68 vs. 0.71, p=0.019). In the GLP-1 group, the TI-RADS (2.60 vs. 2.69, p=0.007) levels increased, while the fT4 (1.26 vs. 1.17, p=0.005) levels decreased. However, linear regression did not show significant association between GLP-1 and post-treatment differences in thyroid function or thyroid nodule.Conclusions: GLP-1 receptor agonists treatment of 12 months in patients with diabetes is considered relatively safe regarding thyroid disease although there is a potential risk for decreasing of fT4 levels and nodule growth/progression, with no clear evidence of superiority over other antidiabetic treatments.","PeriodicalId":11682,"journal":{"name":"Endocrine Practice","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144706755","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Artificial Intelligence in Diabetes Care: Applications, Challenges, and Opportunities Ahead. 人工智能在糖尿病护理中的应用、挑战和机遇。

IF 3.7 3区医学

Endocrine Practice Pub Date : 2025-07-17 DOI: 10.1016/j.eprac.2025.07.008

Rohit Parab, Jenna M Feeley, Maria Valero, Laya Chadalawada, Gian-Gabriel P Garcia, Sudeshna Sil Kar, Anant Madabhushi, Marc D Breton, Jing Li, Hui Shao, Francisco J Pasquel

{"title":"Artificial Intelligence in Diabetes Care: Applications, Challenges, and Opportunities Ahead.","authors":"Rohit Parab, Jenna M Feeley, Maria Valero, Laya Chadalawada, Gian-Gabriel P Garcia, Sudeshna Sil Kar, Anant Madabhushi, Marc D Breton, Jing Li, Hui Shao, Francisco J Pasquel","doi":"10.1016/j.eprac.2025.07.008","DOIUrl":"https://doi.org/10.1016/j.eprac.2025.07.008","url":null,"abstract":"Artificial intelligence (AI) is rapidly transforming clinical medicine, and its potential impact on diabetes care is particularly noteworthy. In recent years, both traditional machine learning approaches and deep learning algorithms have been applied to improve screening for complications of diabetes such as retinopathy, macular edema, and neuropathy, predict disease progression risk, and enhance clinical decision support systems for diagnosis, prognosis, and treatment optimization. AI-driven solutions are also emerging to identify noninvasive biomarkers for detecting diabetes and prediabetes, analyze the macronutrient content of meals using image-based deep learning methods, integrate novel risk prediction tools within electronic health records, and optimize automated insulin delivery (AID) systems. These advancements hold promise for streamlining patient care, personalizing treatment plans, and ultimately improving clinical outcomes. In this narrative review, we examine the latest AI applications in diabetes care, exploring their capabilities, limitations, and the future directions necessary to realize their full potential to improve the care of people living with diabetes.","PeriodicalId":11682,"journal":{"name":"Endocrine Practice","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144667418","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Management of Primary Hyperparathyroidism: Historical and Contemporary Perspectives. 原发性甲状旁腺功能亢进的治疗：历史与当代观点。

IF 3.7 3区医学

Endocrine Practice Pub Date : 2025-07-17 DOI: 10.1016/j.eprac.2025.07.009

Sheryl T Y Htoo, Natalie E Cusano

{"title":"Management of Primary Hyperparathyroidism: Historical and Contemporary Perspectives.","authors":"Sheryl T Y Htoo, Natalie E Cusano","doi":"10.1016/j.eprac.2025.07.009","DOIUrl":"https://doi.org/10.1016/j.eprac.2025.07.009","url":null,"abstract":"Primary hyperparathyroidism (PHPT) is a frequently diagnosed endocrine condition most commonly caused by a single parathyroid adenoma. Our understanding of the epidemiology and management of PHPT have evolved in the past few decades. Asymptomatic PHPT has been the most common presentation in developed countries since the advent of routine biochemical screening. Symptomatic disease is now also decreasing in developing nations. Normocalcemic PHPT is a newer phenotype that can be diagnosed in the setting of elevated PTH concentrations with persistently normal serum calcium, however, evaluation for secondary causes of hyperparathyroidism is critical as it is a diagnosis of exclusion. Genetic testing can be helpful in patients younger than 30 years of age and/or patients with intermediate or equivocal ranges of the urinary calcium to creatinine ratio (between 0.01 and 0.02) to differentiate PHPT from FHH and to evaluate for other genetic etiologies that may affect management. Surgery is the recommended treatment modality for symptomatic PHPT, and patients with asymptomatic PHPT meeting recommended criteria should also be considered for parathyroidectomy. \"Asymptomatic\" patients should be screened for the presence of nephrolithiasis and/or vertebral fracture, since many will be reclassified as having symptomatic disease with further investigation. For poor surgical candidates or patients not meeting criteria for surgery, medical therapy includes cinacalcet for hypercalcemia and antiresorptive therapies for osteoporosis.","PeriodicalId":11682,"journal":{"name":"Endocrine Practice","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144667420","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prognostic Factors and Survival Outcomes in Thyroid Cancer Patients with Bone Metastasis: Insights from a Population-Based Cohort Study. 甲状腺癌骨转移患者的预后因素和生存结果：一项基于人群的队列研究的见解

IF 3.7 3区医学

Endocrine Practice Pub Date : 2025-07-16 DOI: 10.1016/j.eprac.2025.07.010

Hang Zhao, Xiaozhun Tang, Duoping Wang, Peng-Cheng Yu, Cong He, Xu-Feng Chen, Wei-Dong Ye, Jia-Hao Wu, Jia-Qian Hu, Yu-Long Wang

{"title":"Prognostic Factors and Survival Outcomes in Thyroid Cancer Patients with Bone Metastasis: Insights from a Population-Based Cohort Study.","authors":"Hang Zhao, Xiaozhun Tang, Duoping Wang, Peng-Cheng Yu, Cong He, Xu-Feng Chen, Wei-Dong Ye, Jia-Hao Wu, Jia-Qian Hu, Yu-Long Wang","doi":"10.1016/j.eprac.2025.07.010","DOIUrl":"https://doi.org/10.1016/j.eprac.2025.07.010","url":null,"abstract":"Objectives: Thyroid cancer (TC) is the most common endocrine malignancy, and bone metastasis (BM) is the second most common type of metastasis after lung metastasis. BM is associated with a poor prognosis; however, relevant research remains limited. This study aims to evaluate the prognostic factors and survival outcomes in patients with thyroid cancer with bone metastasis (TCBM).Methods: Data from patients with thyroid cancer with bone metastasis were extracted from the Surveillance, Epidemiology, and End Results (SEER) database. Univariable and multivariable Cox proportional hazards regression models were used to identify survival predictors. Survival outcomes were calculated using the Kaplan-Meier method and compared using the log-rank tests.Results: A total of 696 TCBM patients from 2010 to 2021 were included in this study. For the TCBM patients, those age ≥55 years (P < 0.001); those with anaplastic thyroid cancer (P < 0.001); those with brain, liver and lung metastases (all P < 0.05); and those with T4 stage disease (P = 0.011) exhibited significantly worse overall survival (OS), with radioisotope therapy (P < 0.001) significantly improved OS. Additionally, significant factors for cancer-specific survival (CSS) included ATC (P < 0.001); liver and lung metastases (all P < 0.001); and radioisotope treatment (P < 0.001).Conclusion: Our study revealed the critical role of age, pathological subtype, metastatic lesions, and radioisotope therapy in determining the prognosis of TCBM. These findings contribute to providing more rational treatment decisions and risk stratification for TCBM patients.","PeriodicalId":11682,"journal":{"name":"Endocrine Practice","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144667421","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Chronic Hypoparathyroidism - Current and Emerging Therapies. 慢性甲状旁腺功能减退-当前和新兴的治疗方法。

IF 3.7 3区医学

Endocrine Practice Pub Date : 2025-07-16 DOI: 10.1016/j.eprac.2025.07.011

Sarah Khan, Aliya A Khan

{"title":"Chronic Hypoparathyroidism - Current and Emerging Therapies.","authors":"Sarah Khan, Aliya A Khan","doi":"10.1016/j.eprac.2025.07.011","DOIUrl":"https://doi.org/10.1016/j.eprac.2025.07.011","url":null,"abstract":"Hypoparathyroidism (HypoPT) is a rare endocrine disorder characterized by low serum calcium due to insufficient parathyroid hormone (PTH) and results in significant complications. Conventional treatment for hypoparathyroidism with calcium salts and activated vitamin D has limitations such as inadequate control of symptomatic hypocalcemia and large pill burden. PTH replacement therapy offers a more physiologic alternative to conventional therapy. PTH (1-34) has a short half-life of 1 hour and is used off-label for the treatment of hypoparathyroidism. rhPTH (1-84) has a half life of 3 hours and improves symptom control but its production is being halted due to manufacturing issues. Palopegteriparatide has a 60-hour half life and results in an infusion like PTH release profile. This molecule is effective in lowering urinary calcium, maintaining serum eucalcemia, lowering serum phosphate and reducing pill burden and is now approved by the FDA and EMA. Emerging therapies include Eneboparatide which is currently being evaluated in phase 3 clinical trials. Encalaret is a calcilytic molecule which is in phase 3 clinical trials and is a promising molecule for autosomal dominant hypocalcemia type 1. New molecules include an oral PTH1receptor agonist which is in phase 1 clinical trials. A weekly PTH molecule is also being evaluated in phase 2 clinical trials.","PeriodicalId":11682,"journal":{"name":"Endocrine Practice","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144667419","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Impact of vitamin D and calcium on falls and fractures in older adults. 维生素D和钙对老年人跌倒和骨折的影响。

IF 3.7 3区医学

Endocrine Practice Pub Date : 2025-07-14 DOI: 10.1016/j.eprac.2025.07.007

Bess Dawson-Hughes

引用次数: 0

Factors of Composite Target of Time in Range and Time below Range among Children and Adolescents with Type 1 Diabetes Mellitus Using Open-Source Automated Insulin Delivery. 儿童青少年1型糖尿病患者应用开源自动胰岛素给药时间在范围内和低于范围的综合目标因素

IF 3.7 3区医学

Endocrine Practice Pub Date : 2025-07-14 DOI: 10.1016/j.eprac.2025.07.006

Mengyun Lei, Yongwen Zhou, Chaofan Wang, Ping Ling, Ying Ni, Daizhi Yang, Xubin Yang, Wen Xu, Hongrong Deng, Jinhua Yan

{"title":"Factors of Composite Target of Time in Range and Time below Range among Children and Adolescents with Type 1 Diabetes Mellitus Using Open-Source Automated Insulin Delivery.","authors":"Mengyun Lei, Yongwen Zhou, Chaofan Wang, Ping Ling, Ying Ni, Daizhi Yang, Xubin Yang, Wen Xu, Hongrong Deng, Jinhua Yan","doi":"10.1016/j.eprac.2025.07.006","DOIUrl":"https://doi.org/10.1016/j.eprac.2025.07.006","url":null,"abstract":"Objectives: To explore glycemic outcomes after open-source Android artificial pancreas system (AAPS) use and factors of achieving composite target (time in range of 70-180mg/dL [TIR]>70% and time below range of 70mg/dL [TBR70] <4%) among children and adolescents with type 1 diabetes mellitus (T1DM).Methods: T1DM people aged under 18 years and who used AAPS for ≥6 months were included. Continuous glucose monitoring (CGM) metrics were calculated after 3 and 6 months of AAPS use. Logistic regression model was used to explore factors of achieving composite target at 6 months.Results: Seventy-seven participants (44.16% male) were included. Median age was 10.64(6.90,12.72) years, T1DM duration was 2.03(0.59,4.43) years and baseline HbA1c was 7.78±2.12%. After 3 and 6 months, 67.53% and 66.23% achieved TIR>70%, while 57.14% and 54.55% achieved TBR70<4%, respectively. After 3 months, the achievement rate composite target was 41.56 % and slightly declined to 35.06 % at 6 months(P>0.05). The age at AAPS initiation (OR=1.32), T1DM duration (OR=0.72), and frequency of daily meal announcements (OR=1.40) were associated factors of achieving composite target at 6 months (all P<0.05).Conclusions: T1DM children and adolescents with older age, shorter T1DM duration at AAPS initiation, and higher meal announcement frequency during AAPS use had the potential to successfully achieve composite target.","PeriodicalId":11682,"journal":{"name":"Endocrine Practice","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144648865","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Growth hormone and bone: pre-clinical and clinical perspectives. 生长激素和骨骼：临床前和临床观点。

IF 3.7 3区医学

Endocrine Practice Pub Date : 2025-07-14 DOI: 10.1016/j.eprac.2025.07.005

Kevin Cj Yuen

{"title":"Growth hormone and bone: pre-clinical and clinical perspectives.","authors":"Kevin Cj Yuen","doi":"10.1016/j.eprac.2025.07.005","DOIUrl":"https://doi.org/10.1016/j.eprac.2025.07.005","url":null,"abstract":"Objective: Growth hormone (GH) is essential for growth and bone metabolism. This article reviews pre-clinical data that has shaped our understanding of the mechanisms underpinning the effects of GH on bone beyond the downstream activation of IGF-I generation and summarizes the clinical data of GH deficiency (GHD) and acromegaly on bone health parameters and fracture risk.Methods: A literature search was conducted on PubMed using the following key words: growth hormone, IGF-I, bone, growth hormone deficiency and acromegaly. The discussion of therapy in GHD and acromegaly patients, and their fracture risk assessment was based on evidence derived from previously published pre-clinical and clinical studies.Results: Pre-clinical and clinical data have demonstrated important pleiotropic effects of GH and IGF-I on bone formation and resorption. Growth hormone exerts direct and IGF-dependent and independent effects on bone, while IGF-I acts in an endocrine and autocrine/paracrine manner. In GHD, decreased bone turnover, delayed statural growth, low bone mass, and increased fracture risk are observed, whereas acromegaly is associated with increased bone turnover but decreased lumbar bone mineral density and increased vertebral fracture and osteoarthritis risk. Treatment aimed at normalizing the GH/IGF-I axis decreases the fracture risk in GHD, but not acromegaly.Conclusion: Pre-clinical and clinical studies have improved our understanding of the role of GH in bone in healthy individuals and in disease states. More research is needed to identify the effects of GH on bone and to determine how best to treat GHD and acromegaly patients, so that their bone health is optimized.","PeriodicalId":11682,"journal":{"name":"Endocrine Practice","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144648876","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0